Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.69 USD
Change Today -0.01 / -0.59%
Volume 83.4K
AMRS On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

amyris inc (AMRS) Key Developments

Amyris & Genome Compiler Launch Testing Program for Pharma and Biotech Companies to Explore DNA Design and Construction Solutions

Amyris, Inc. and Genome Compiler Corp. announced the availability of an open testing program for pharma and biotech companies to explore DNA design and construction solutions. The two companies announced a collaboration agreement in March 2015 to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly. Today, the companies are extending an open invitation to interested parties to visit Genome Compiler's website page where they can source helpful information and express their interest in the program. Through the integrated platform, researchers can leverage a comprehensive solution from design to delivery that represents a first-of-its-kind integrated DNA design and construction service. The service allows for greater levels of automation, enabling faster progress, and will be less expensive and more sophisticated than other available offerings. Prospective customers will have access to Genome Compiler's advanced software tools, along with Amyris's extensive libraries of verified genetic parts, DNA construction and editing methods, all derived from its expertise in innovative bioscience technology.

Amyris, Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for 2015

Amyris, Inc. reported consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $7,843,000 compared with $9,307,000 for the same period last year. Loss from operations was $28,659,000 compared with $24,402,000 for the same period last year. Loss before income taxes and loss from investments in affiliates was $46,420,000 compared with $35,175,000 for the same period last year. Net loss attributable to Amyris, Inc. common stockholders was $47,130,000 or $0.62 diluted per share compared with $35,479,000 or $0.45 diluted per share for the same period last year. Net loss attributable to Amyris, Inc. common stockholders (Non-GAAP) was $37,338,000 or $0.47 diluted per share compared with $27,462,000 or $0.35 diluted per share for the same period last year. Negative adjusted Free Cash flow was $30.2 million, compared to $26.7 million for the second quarter of 2014 driven by timing of collaboration inflows, increased marketing spend and lower adjusted gross margins in the quarter. Cash revenue inflows, a non-GAAP measure, totaled $5.2 million for the second quarter of 2015. Collaboration and grants inflows decreased from $3.8 million in the second quarter of 2014 to $1.9 million in the second quarter of 2015. This decline was mostly driven by timing of contracts and the choppiness related to collaboration negotiations. For the six months, the company reported total revenues of $15,715,000 compared with $15,348,000 for the same period last year. Loss from operations was $53,821,000 compared with $51,089,000 for the same period last year. Loss before income taxes and loss from investments in affiliates was $97,759,000 compared with $18,708,000 for the same period last year. Net loss attributable to Amyris, Inc. common stockholders was $99,370,000 or $1.25 diluted per share compared with $19,094,000 or $0.66 diluted per share for the same period last year. Net loss attributable to Amyris, Inc. common stockholders (Non-GAAP) was $69,514,000 or $0.87 diluted per share compared with $55,533,000 or $0.71 diluted per share for the same period last year. The decline was driven by unfavorable foreign currency fluctuations of approximately $0.5 million and transition away from low value fuel sales. Cash revenue inflows, a non-GAAP measure, totaled $35.5 million for the six months ended June 30, 2015. This is a 36% increase compared to $26.1 million for the same period of 2014. Adjusted Free Cash flow for the first half of 2015 was -$23.7 million, an improvement of $14.2 million compared to the first half of 2014, driven by collaboration inflows, including with Total, as well as improved adjusted gross margins. For 2015, GAAP revenues will be in the range of $63 million to $75 million for the full year 2015 with the large range driven largely by the expectations related to the timing of closing collaborations and finalizing terms that may impact revenue recognition timing. Non-GAAP cash revenue inflows is in the range of $82 million to $102 million for the full year 2015, with the large range driven by the expected timing of closing collaborations in pipeline. This aligns with the product portfolio post-restructuring of the joint venture with Total. Cash revenue inflows through June 30, 2015 was $35.5 million.

Amyris, Inc. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 03:20 PM

Amyris, Inc. Presents at Jefferies 11th Annual Industrials Conference, Aug-10-2015 03:20 PM. Venue: Grand Hyatt, 109 E. 42nd Street, New York, New York, United States.

Amyris, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Amyris, Inc. announced that they will report Q2, 2015 results at 4:30 PM, US Eastern Standard Time on Aug 06, 2015

Amyris, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Amyris, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMRS:US $1.69 USD -0.01

AMRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
China Clean Energy Inc $0.03 USD 0.00
Gevo Inc $2.33 USD -0.02
Methes Energies International Ltd $0.33 USD -0.0099
Parabel Inc $0.52 USD 0.00
Solazyme Inc $2.52 USD +0.14
View Industry Companies
 

Industry Analysis

AMRS

Industry Average

Valuation AMRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.1x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMYRIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.